Combined inhibition of EZH2 and DNMT1 augmented the expression of the inflammatory chemokines CXCL9 and CXCL10, which increased TILs and decreased tumor progression, thus improving the therapeutic efficacy of PD-L1 checkpoint blockade and adoptive T-cell transfusion in tumor-bearing mice [248]. Here, CXCL9 is linked to neoplasm.